A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks

Exclusion Criteria

• •CLINICAL
• •Maximal systolic blood pressure \<80 mmHg AFTER initial fluid and/or pressor resuscitation
• •Uncontrolled hypertension (SBP\>180 OR DBP \>110) at time of enrollment
• •Ventricular fibrillation or ventricular tachycardia requiring DC cardioversion
• •Sinus bradycardia (HR \<50/min), third degree or advanced second degree heart block.
• •Known pregnancy
• •New or suspected new left bundle branch block
• •BIOCHEMICAL
• •Known thrombocytopenia (platelet count \<100,000)
• •Known severe renal insufficiency (creatinine \>4.0 mg/dL)
• •INCREASED BLEEDING RISK
• •Active or recent (\<1 year) bleeding or gastrointestinal hemorrhage
• •Major surgery \<1 month
• •Known coagulopathy, platelet disorder or history of thrombocytopenia: If a patient is known to be on chronic warfarin therapy, the International Normalized Ratio (INR) must be known to be \<1.6 in order for the patient to be included
• •Known neoplasm
• •Any history of hemorrhagic cerebrovascular disorder or active intracranial pathology
• •MEDICATIONS
• •Administration of a fibrinolytic agent within 7 days
• •Known allergy or contraindication to eptifibatide OR aspirin OR heparin
• •Treatment with another GP IIb/IIIa inhibitor within 7 days